ArticleFrontiers in allergy2026
Tezepelumab attenuates exertional symptom burden in severe asthma: insights from a real-world cohort.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Exertional symptom burden is an important yet insufficiently characterised component of morbidity in severe asthma. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations and improves asthma control across phenotypes, but its effects on patient-reported exertional symptoms and physical activity limitation remain unclear. Methods: We conducted a retrospective study in 24 adults with severe asthma initiating tezepelumab per GINA criteria. The 6-item Asthma Control Questionnaire (ACQ-6), Asthma Control Test (ACT), and mini-Asthma Quality of Life Questionnaire (miniAQLQ) were administered at baseline and at 3 ( Results: At baseline, patients had poorly controlled asthma (median ACQ-6 3.50/6, ACT 11/25, miniAQLQ 3.53/6) and moderate-to-severe airflow limitation (median FEV₁ 57% predicted). Total scores improved progressively over 12 months, with changes at months 6 and 12 exceeding the respective minimal clinically important differences. Exertion-related items showed consistent improvements at least as pronounced as total score changes. The largest improvements were in strenuous activity limitation (miniAQLQ Q12: median change +2.0, Conclusion: In severe asthma, Tezepelumab is associated with progressive attenuation of exertional symptoms over 12 months of real-world treatment. These associative findings are consistent with mechanistic data and support further prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.